Cost effectiveness of the type II Boston keratoprosthesis

Eye

Volumn 25, Issue 3, 2011, Pages 342-349

  Ament, J D ^a   Stryjewski, T P ^a   Pujari, S ^a   Siddique, S ^a   Papaliodis, G N ^a   Chodosh, J ^a   Dohlman, C H ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

autoimmune diseases; cost effectiveness; cost utility; decision analysis; keratoprosthesis

Indexed keywords

ADULT; AGED; ARTICLE; BLINDNESS; CLINICAL ARTICLE; COHORT ANALYSIS; CORNEA DISEASE; CORNEA SURGERY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DISEASE SEVERITY; DRY EYE; FEMALE; FOLLOW UP; HUMAN; KERATOPROSTHESIS; MALE; MEDICARE; QUALITY ADJUSTED LIFE YEAR; RETROSPECTIVE STUDY; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; TYPE II BOSTON KERATOPROSTHESIS; VISUAL ACUITY;

EID: 79952588243     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2010.197     Document Type: Article

References (38)

1. Ament JD, Stryjewski TP, Ciolino JB, Todani A, Chodosh J, Dohlman CH. Cost-Effectiveness of the Boston Keratoprosthesis. Am J Ophthalmol 2010; 149(2): 221-228.
2. Foster CS. Immunologic disorders of the conjunctiva, cornea, and sclera. In: Albert DM, Jakobiec FA (eds). Principles and practice of ophthalmology, 2nd ed Philadelphia, Pennsylvania: WB Saunders, 1999; 821-823.
3. Tugal-Tutkun I, Akova YA, Foster CS. Penetrating keratoplasty in cicatrizing conjunctival diseases. Ophthalmology 1995; 102: 576-585.
4. Solomon A, Ellies P, Anderson DF, Touhami A, GrueterichM, Espana EM et al. Long-term outcome of keratolimbal allograft with or without penetrating keratoplasty for total limbal stem cell deficiency. Ophthalmology 2002; 109: 1159-1166. (Pubitemid 34546927)
5. Dohlman CH, Doane M. Keratoprosthesis in end-stage dry eye. Adv Exp Med Biol 1994; 350: 561-564. (Pubitemid 24130690)
6. Dohlman CH, Terada H. Keratoprosthesis in pemphigoid and Stevens-Johnson syndrome. Adv Exp Med Biol 1998; 438: 1021-1025. (Pubitemid 128699441)
7. Yaghouti F, Nouri M, Abad JC, Power WJ, Doane MG, Dohlman CH. Keratoprosthesis: preoperative prognostic categories. Cornea 2001; 20: 19-23. (Pubitemid 32038149)
8. Sayegh RR, Ang LPK, Foster S, Dohlman CH. The Boston Keratoprosthesis in Stevens-Johnson Syndrome. Am J Ophthalmol 2008; 145(3): 438-444.
9. Geerling G, Liu CSC, Collin JRO, Dart JKG. Costs and gains of complex procedures to rehabilitate end stage ocular surface disease. Br J Ophthalmol 2002; 86: 1220-1221. (Pubitemid 35238596)
10. Falcinelli G, Falsini B, Taloni M, Colliardo P, Falcinelli G. Modified osteo-odonto-keratoprosthesis for treatment of corneal blindness: long-term anatomical and functional outcomes in 181 cases. Arch Ophthalmol 2005; 123(10): 1319-1329. (Pubitemid 41429731)
11. Liu C, Okera S, Tandon R, Herold J, Hull C, Thorp S. Visual rehabilitation in end-stage inflammatory ocular surface disease with the osteo-odonto-keratoprosthesis: results from the UK. Br J Ophthalmol 2008; 92(9): 1211-1217.
12. Dohlman JG, Foster CS, Dohlman CH. Boston Keratoprosthesis in Steven-Johnson Syndrome: a case of using infliximab to prevent tissue necrosis. DJO 2009; 15(1).
13. Aldave AJ, Kamal KM, Vo RC, Yu F. The Boston type I keratoprosthesis: improving outcomes and expanding indications. Ophthalmology 2009; 116(4): 640-651.
14. Brown MM, Brown GC. How to interpret a healthcare economic analysis. Curr Opin Ophthalmol 2005; 16(3): 191-194. (Pubitemid 40694980)
15. Brown GC, Brown MM, Sharma S. Health care economic analyses. Retina 2004; 24(1): 139-146.
16. Dohlman CH, Harissi-Dagher M, Khan BF, Sippel K, Aquavella JV, Graney JM. Introduction to the use of the Boston keratoprosthesis. Expert Rev Ophthalmol 2006; 1(1): 41-48.
17. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-effectiveness in Health and Medicine. Oxford University Press: New York, 1996; 1-413.
18. Brown MM, Brown GC, Sharma S, Garrett S. Evidencebased medicine, utilities, and quality of life. Curr Opin Ophthalmol 1999; 10(3): 221-226. (Pubitemid 29263948)
19. Hirneiss C, Neubauer AS, Niedermeir A, Messmer EM, Ulbig M, Kampik A. Cost utility for penetrating keratoplasty in patients with poor binocular vision. Ophthalmology 2006; 113: 2176-2180. (Pubitemid 44838907)
20. McCabe C, Claxton K, Culyer AJ. The NICE cost-effectiveness thresholdFWhat it is and what that means. Pharmacoeconomics 2008; 26(9): 733-744.
21. Devlin N, Parkin D. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ 2004; 13(5): 437-452. (Pubitemid 38660393)
22. Summary of VELCADE Response Scheme. National Institute for Health and Clinical Excellence, October 2008. Available at http://www.nice.org.uk/ nicemedia/pdf/ MyelomaDofHSummaryResponderScheme.pdf. Accessed 30 January 2010.
23. CPI Inflation Calculator. U.S. Bureau of Labor Statistics: Washington, DC, 2010 Available at http://www.bls.gov/ data/inflation-calculator.htm. Accessed on: March 3.
24. Busbee BG, Brown MM, Brown GC, Sharma S. Incremental cost-effectiveness of initial cataract surgery. Ophthalmology 2002; 109(3): 606-612. (Pubitemid 34184933)
25. Busbee BG, Brown MM, Brown GC, Sharma S. Cost-utility analysis of cataract surgery in the second eye. Ophthalmology 2003; 110(12): 2310-2317. (Pubitemid 37485160)
26. Sharma S, Brown GC, Brown MM, Hollands H, Shah GK. The cost-effectiveness of photodynamic therapy for fellow eyes with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology 2001; 108(11): 2051-2059. (Pubitemid 33032778)
27. Losina E, Walensky RP, Kessler CL, Emrani PS, Reichmann WM, Wright EA et al. Cost-effectiveness of total knee arthroplasty in the United States. Arch Intern Med 2009; 169(12): 1113-1121.
28. Cummins JS, Tomek IM, Kantor SR, Furnes O, Engesaeter LB, Finlayson SR. Cost-effectiveness of antibiotic-impregnated bone cement used in primary total hip arthroplasty. J Bone Joint Surg Am 2009; 91(3): 634-641.
29. Griffin SC, Barber JA, Manca A, Sculpher MJ, Thompson SG, Buxton MJ et al. Cost effectiveness of clinically appropriate decisions on alternative treatments for angina pectoris: prospective observational study. BMJ 2007; 334(7594): 624-628. (Pubitemid 46852481)
30. Pinkerton SD, Holtgrave DR, Pinkerton HJ. Costeffectiveness of chemoprophylaxis after occupational exposure to HIV. Arch Intern Med 1997; 157(17): 1972-1980. (Pubitemid 27398361)
31. Dayton JD, Kanter KR, Vincent RN, Mahle WT. Costeffectiveness of pediatric heart transplantation. J Heart Lung Transplant 2006; 25(4): 409-415.
32. Kontodimopoulos N, Niakas D. An estimate of lifelong costs and QALYs in renal replacement therapy based on patients' life expectancy. Health Policy 2008; 86(1): 85-96. (Pubitemid 351296306)
33. Xie F, Lo NN, Tarride JE, O'Reilly D, Goeree R, Lee HP. Total or partial knee replacement? Cost-utility analysis in patients with knee osteoarthritis based on a 2-year observational study. Eur J Health Econ 2010; 11(1): 27-34.
34. Chang RW, Pellisier JM, Hazen GB. A cost-effectiveness analysis of total hip arthroplasty for osteoarthritis of the hip. JAMA 1996; 275(11): 858-865. (Pubitemid 26087223)
35. Mushlin AI, Mooney C, Holloway RG, Detsky AS, Mattson DH, Phelps CE. The cost-effectiveness of magnetic resonance imaging for patients with equivocal neurological symptoms. Int J Technol Assess Health Care 1997; 13(1): 21-34. (Pubitemid 27138805)
36. Faucett SC, Genuario JW, Tosteson AN, Koval KJ. Is prophylactic fixation a cost-effective method to prevent a future contralateral fragility hip fracture? J Orthop Trauma 2010; 24(2): 65-74.
37. Jacobson JJ, Schweitzer SO, Kowalski CJ. Chemoprophylaxis of prosthetic joint patients during dental treatmentFa decision-utility analysis. Oral Surgery Oral Med Oral Pathol 1991; 72(2): 167-177.
38. Geerling G, Liu CS, Collin JR, Dart JK. Costs and gains of complex procedures to rehabilitate end stage ocular surface disease. Br J Ophthalmol 2002; 86(11): 1220-1221. (Pubitemid 35238596)